Shanghai Fosun Pharmaceutical (02196) announced its interim results, with a net profit excluding non-recurring items of approximately 1.144 billion yuan, representing a year-on-year increase of 19.09%.

Shanghai Fosun Pharmaceutical (02196) announced its interim results for 2026, with operating revenue of approximately 20.442 billion yuan, a year-on-year increase of 4.75%; net profit attributable to shareholders of the listed company is approximately 1.721 billion yuan, a year-on-year increase of 1.15%; the net profit excluding non-recurring gains and losses is approximately 1.144 billion yuan, a year-on-year increase of 19.09%; basic earnings per share are 0.65 yuan. The net cash flow generated from operating activities is approximately 2.424 billion yuan, a year-on-year increase of 13.59%. The announcement stated that the revenue growth is mainly attributed to robust growth in innovative pharmaceuticals and overseas business; excluding the impact of exchange rate fluctuations, the year-on-year increase is 7.17%. During the reporting period, the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, increased by 19.09% year-on-year, primarily due to steady revenue growth; excluding the impact of exchange rate fluctuations, the year-on-year increase is 21.97%.